As competition for research funding increases, the Pfizer ARTS award program underscores Pfizer’s commitment to supporting investigators with an interest in advancing their academic research.
MissionThe mission of the Pfizer ARTS award program is to support basic and clinical science through a competitive, independent peer-reviewed program that advances the understanding and medical knowledge of mTOR pathway inhibition in transplantation and related areas.
BackgroundBasic science and clinical research continue to advance our knowledge and understanding of mTOR inhibition and its role in transplantation, immunity and inflammation. However, the clinical applicability of these findings is not always apparent and correlative studies may not be readily available.
The Pfizer ARTS award program is designed to support research in areas related to mTOR pathway inhibition, both mechanistic and clinical.
Pfizer is hopeful that the outcomes of this research program will contribute to the knowledge of mTOR pathway inhibition and its potential effect on improving patient health.
Areas of Research FocusPfizer will support clinical and basic science research exploring mTOR pathway inhibition in the following areas:
- mechanisms of alloimmunity and allograft injury
- mechanisms of cellular and molecular responses
- pharmacogenomics and pharmacogenetics in transplantation
- mechanisms, incidence and treatment of adverse events
- patient outcomes in transplantation
- novel applications in areas of unmet medical need